Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

International Journal of Antimicrobial Agents

Volumn 32, Issue 5, 2008, Pages 378-385

  Hsu, Donald I ^a   Hidayat, Levita K ^b   Quist, Ryan ^a   Hindler, Janet ^c   Karlsson, Asa ^d   Yusof, Anne ^d   Wong Beringer, Annie ^b,e  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d AB Biodisk Research Laboratories   (Sweden)

^e HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

hGISA; Testing; Vancomycin susceptibility

Indexed keywords

LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BIOASSAY; BROTH DILUTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OBSERVATIONAL STUDY; PHENOTYPE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RELIABILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE; YOUNG ADULT;

EID: 53249154277     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.05.007     Document Type: Article

References (26)

1. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
2. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., et al. Comparison of community and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
3. Salgado C., Farr B., and Calfee D. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 36 (2003) 131-139
4. Bolmstrom A., Karlsson A., Mills K., Ho P., Fang H., and Hedin G. First report of hetero-GISA among genetically diverse MRSA isolated from 1996 to 2005 in Southern Stockholm, Sweden. Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 16-19 December 2005, Washington, DC (2005), ASM Press, Washington, DC [Abstract C2-302]
5. Hidayat L.K., Hsu D.I., Quist R., Shriner K., and Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166 (2006) 2138-2144
6. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentagg J.J., Forrest A., and Moellering Jr. R.C. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38 (2004) 1700-1705
7. Sakoulas G., Moise-Broder P.A., Schentag J.J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
8. Walsh T.R., Bolmstrom A., Qwarnstrom A., Ho P., Wootton M., Howe R.A., et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39 (2001) 2439-2444
9. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42 Suppl. 1 (2006) S13-S24
10. Howden B.P., Ward P.B., Charles P.G., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
11. Aeschlimann J.R., Hershberger E., and Rybak M.J. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999) 1914-1918
12. Boyle-Vavra S., Berke S.K., Lee J.C., and Daum R.S. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 44 (2000) 272-277
13. Wootton M., MacGowan A.P., Walsh T.R., and Howe R.A. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 45 (2007) 329-332
14. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
15. Garnier F., Chainier D., Walsh T., Karlsson A., Bolmstrom A., Grelaud C., et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 57 (2006) 146-149
16. Bolmstrom A., Engelhardt A., and Bylund L. Evaluation of a new E test vancomycin (VA) + teicoplanin (TP) strip for detection of GISA/hGISA. Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 16-19 December 2005, Washington, DC (2005), ASM Press, Washington, DC [Abstract D-1735]
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. M100-S15. Wayne, PA: CLSI; 2005.
18. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988) 128-140
19. Moise P.A., Forrest A., Birmingham M.C., and Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 50 (2002) 1017-1026
20. Moise P.A., and Schentag J.J. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 16 Suppl. 1 (2000) S31-S34
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth information supplement. M100-S17. Wayne, PA: CLSI; 2007.
22. Tenover F.C., and Moellering Jr. R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44 (2007) 1208-1215
23. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
24. Sancak B., Ercis S., Menemenlioglu D., Colakoglu S., and Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56 (2005) 519-523
25. Charles P.G., Ward P.B., Johnson P.D., Howden B.P., and Grayson M.L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
26. Appelbaum P.C. Microbiology of antibiotic resistance in Staphylococcus aureus. Clin Infect Dis 45 Suppl. 3 (2007) S165-S170